i+solutions

In the fight against HIV, we face a defining moment. Ending AIDS is finally on the horizon. But we must invest now to finish what we started. With sustained investment and steadfast commitment, we can reduce new infections and turbocharge progress to an AIDS-free generation. #DefeatHIV https://lnkd.in/e7rFRKeb

The Global Fund, together with Unitaid and Stop TB’s Global Drug Facility (GDF), Invite TB Medicine Suppliers to Submit Dossiers for Needed TB Formulations The Ad Hoc list prioritizes medicines most urgently in need of development: adult versions of pretomanid and delamanid for use in DR-TB treatment, fixed-dose formulations (FDC) of rifapentine/isoniazid/moxifloxacin to support shorter DS-TB treatment, and rifampicin-based 4-FDCs to address global supply constraints in DS-TB medicines. These, and other medicines are included in the 30th Round of Expressions of Interest (EOI) for the Global Fund Expert Review Panel (ERP). https://lnkd.in/emj6NshN The Global Fund ERP plays a critical role in expediting availability of new TB formulations, providing an interim quality approval status that allows procurement by Global Fund, GDF, and others, whilst products undergo full review by the WHO Prequalification Programme. Behind the scenes, the TB community collaboratively aligns on which products to recommend for inclusion in the Global Fund ERP EOI and which of these to prioritize for fastest possible assessment and availability. The WHO Global TB Programme and GDF conduct analyses and share draft recommendations with many stakeholders organized under the TB Procurement and Market-Shaping Action Team (TPMAT). Comments and discussion ensue until a consensus is reached on which products to recommend and prioritize. The TPMAT includes staff from WHO, the Global Fund, Stop TB Partnership’s GDF, Unitaid, Médecins Sans Frontières (MSF), Treatment Action Group (TAG), National TB Programmes, researchers, clinicians, implementers, and many more. This is one step of many organized under the GDF-led TPMAT to proactively identify and address potential development, supply, and regulatory barriers to new TB product development. From horizon scanning to identify needed products, to sending supplier signals and developing supplier incentives, to supporting regulatory prioritization. 

Tuberculosis has threatened humanity for too long. But now the fight against TB has unprecedented momentum with greater leadership, investment and improved diagnostic, treatment and prevention tools. We must invest to finish what we started. We must defeat TB together. #DefeatTB https://lnkd.in/e7rFRKeb

Lenacapavir is an incredible lifesaver, giving 100% protection with a twice yearly injection, reducing fear and stigma for people at risk of contracting HIV, increasing health equity enourmously if we can make it readily available to all who are at risk. This could be the end of AIDS. #leavenoonebehind #hiv #aids #stigma #prevention

🌍 Tackling Non-Communicable Diseases in Low- and Middle-Income Countries is a Global Priority Today the NCD Alliance Forum 2025 kicked off to unite and mobilize key stakeholders to find solutions to reduce the burden caused by NCDs globally. Trip Allport, Chief Growth Officer for XS2Meds is attending on behalf of i+solutions. XS2Meds (www.xs2meds.org) is i+solutions B2B procurement platform addressing the need for equitable access to affordable quality medicines for the treatment of NCDs. Let us know if you want to meet up. Non-communicable diseases (NCDs)—including heart disease, diabetes, cancer, and respiratory illnesses—are often perceived as challenges for high-income nations. However, NCDs have a disproportionate impact on people living in low- and middle-income countries (LMICs), making them a critical global health issue. Despite this, funding and policies remain heavily focused on infectious diseases, leaving millions vulnerable to preventable and manageable conditions. Without urgent action, the burden of NCDs will continue to rise, exacerbating economic strain, deepening health inequalities, and overwhelming healthcare systems. 🔹 What can be done? 💡 Strengthen primary healthcare to integrate NCD prevention and management. 💡 Invest in public health campaigns addressing risk factors like tobacco use, poor nutrition, and physical inactivity. 💡 Ensure equitable access to essential medicines and treatments. 💡 Foster collaboration between governments, the private sector, and civil society to drive sustainable solutions. The fight against NCDs is not just a health issue—it’s an economic and social imperative. By prioritizing NCDs in global health agendas, we can build healthier, more resilient communities and ensure that no one is left behind. #GlobalHealth #NCDs #HealthEquity #SustainableDevelopment #PublicHealth #LMICs #NCDAllianceForum #ActOnNCDs #NCDAF2025

Tanzania is one of over 30 countries where i+solutions is working to install oxygen plants as part of The Global Fund's project to improve access to medical oxygen in low- and middle-income countries. The project started in 2020 at the height of the covid pandemic and is reaching its final stages with many commissionings and handovers happening in the upocoming months. Follow us for further updates! #oxygen #leavenoonebehind #everybreathcounts

The first quarter has been very busy for the i+solutions Oxygen team as we gradually enter the commissioning phase of the PSA plant project in various countries. As challenging as it is to navigate difficult terrain to get this done, our consolation is the impact and the lives that will be saved. This week we are in the Central African Republic to assess the progress of the work. #CHUCOM and #CNHUB hospitals respectively. Novair #medicaloxygen #globalFund #everybreathcounts

XS2Meds is a social enterprise of i+solutions which aims to expand access to medicines and health products through strategic #procurement services to reduce #price, improve #availability and ensure #quality.

When COVID-19 struck five years ago, in low- and middle-income countries, nine out of ten hospitals had no #medical #oxygen capacity, says Peter Sands in the below article in The Economist. In response, close to $1bn was mobilised to help these countries provide emergency supplies of cylinders and to invest in more scalable and cost-effective approaches, such as pressure swing adsorption (PSA) plants that create medical oxygen from the atmosphere. These investments have constituted the biggest expansion in access to medical oxygen such countries have ever seen. i+solutions has been involved from the onset of The Global Fund's project in the #procurement of the PSA plants. These plants can pipe oxygen directly to hospital beds or can be used to fill cylinders that can potentially also be used by other health facilities. Along the way, thorough hospital #site #assessments needed to be done to propose the necessary construction and installation works, so we dedicated a small team and hired a few experienced engineers to help us get the job done. On a daily basis, we are working closely together with our counterparts at The Global Fund, our stakeholders at the country ministry level, and our suppliers listed below, who in turn have their local partners in-country. The size and number of oxygen plants that are installed makes this a very interesting project with a huge #impact, which is only possible thanks to the #full #commitment of all #stakeholders at all levels! A big #thank #you to all. So far, in total 167 hospital sites, have been assessed in over 30 countries around the world. 89 of these sites are currently under construction and 58 sites have already been completed. In the first half of 2025, we expect most remaining sites to be finalized, local staff to be trained in the use of the machines, and the sites handed over to hospital administrations. Compliments to our oxygen team (that consists of only 8 people) for a job well done! AirSep Corporation Atlas Copco BeaconMedaes Afrimed Servymed Ltd BVI Ultra Controlo MIL'S Novair Sinopharm Fortune International Trading Corp. CAN GAS SYSTEMS Sümer Uluslararası Sanayi ve Ticaret A.Ş. Fan Huang Flavio Cerro Frank Rammeloo kingsely Gabs Loic Cohen Ogheneruona Owebor CMRP, R.Engr.Tech,AMEI, MNATE Desiree Salas Pastene Alice Fanicchia

i+academy announces winners of the 9th scholarship programme! In December 2024, i+solutions launched for the 9th year in a row a scholarship programme to award 12 future supply chain experts the opportunity to enrol for free in its online flagship supply chain course on i+academy. Every candidate who fulfilled the conditions for application was accepted in a pool from which the computer randomly chose 12 winners. We received again a nice number of applications from a wide range of countries in Asia and Africa.  The winners will be enrolled in respectively the English and French version of the Basic Principles for Supply Chain Management course, planned to start in February 2025. We congratulate the happy winners Ahmed Mohamed Abdi from World Vision Somalia Onyemuche Amadi from Intersos Nigeria Gamuchirayi J. Matandirotya from MoH Zimbabwe Olivier MURERAMANZI from FDA Rwanda Fredrick Nego from MoH Solomon Islands Muhabaw Teshome from Amhara Ethiopia Akili CISHUGI from Action Santé DRC EKOKO Grace from MoH DRC Nord-Kivu ISSA HAROUNA Moussa from Centre Hospitalier Universitaire Djibouti Fabrica Kadima Mbaji from PNAM DRC Junior Lominghos from MoH DRC Aline Nininahazwe from MoH Burundi District Mpanda We wish you all good luck with your studies and in your future supply chain careers! For more information on the many courses i+academy has to offer, please visit www.iplusacademy.org or write to us at training@iplussolutions.org. #capacitybuilding #onlinetraining #scholarship #publichealth #supplychain